

# Refine Search

## Search Results

Terms	Documents
(epstein david or grate dilara or stanton martin or diener john or wilson charles or mccauley thomas or desouza errol).in. and (cpg or immunostimulatory or iss or rcgyy).clm.	5

Database:

US Pre-Grant Publication Full-Text Database  
US Patents Full-Text Database  
US Patents OCR Backfile  
EPO Abstracts Database  
JPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletin Database

Search Type: ☒ Prior Art ☐ Interference

Search:

L59

Refine Search

Recall Text

Clear

Interrupt

## Search History

DATE: Friday, October 15, 2010

[Purge Queries](#)

[Printable Copy](#)

[Create Case](#)

Set  
Name Query  
Side  
by  
Side

Hit  
Count Set  
Name Result  
Set Set Name  
Grid

*Prior Art Searches*

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ

<a href="#">L59</a>	(epstein david or grate dilara or stanton martin or diener john or wilson charles or mccauley thomas or desouza errol).in. and (cpg or immunostimulatory or iss or rcgyy).clm.	5	<a href="#">L59</a>	<a href="#">L59</a>
<a href="#">L58</a>	(epstein david or dilare grate or stanton martin or diener john or wilson charles or mccauley thomas or desouza errol).in. and (cpg or immunostimulatory or iss or rcgyy).clm.	5	<a href="#">L58</a>	<a href="#">L58</a>
<a href="#">L57</a>	(epstein david or dilara grate or stanton martin or diener john or wilson charles or mccauley thomas or desouza errol).in. and (cpg or immunostimulatory or iss or rcgyy).clm.	5	<a href="#">L57</a>	<a href="#">L57</a>
<a href="#">L56</a>	L55 not controlled pore glass	110	<a href="#">L56</a>	<a href="#">L56</a>
<a href="#">L55</a>	aptamer same cpg	130	<a href="#">L55</a>	<a href="#">L55</a>
<a href="#">L54</a>	6229002.pn. and ((peg or high) same (stable or stabil\$))	1	<a href="#">L54</a>	<a href="#">L54</a>
<a href="#">L53</a>	6229002.pn. and (stable or stabil\$)	1	<a href="#">L53</a>	<a href="#">L53</a>

<u>L52</u>	6229002.pn. and (peg or polyethylene\$)	2	<u>L52</u>	<u>L52</u>
<u>L51</u>	6229002.pn.	2	<u>L51</u>	<u>L51</u>
<u>L50</u>	stabilized aptamers	62	<u>L50</u>	<u>L50</u>
<i>DB=USPT,EPAB,DWPI; PLUR=YES; OP=ADJ</i>				
<u>L49</u>	\$TGACTGTGAACGTTTCGAGATGA\$	52	<u>L49</u>	<u>L49</u>
<i>DB=USPT; PLUR=YES; OP=ADJ</i>				
<u>L48</u>	7001890.pn. and cpg	1	<u>L48</u>	<u>L48</u>
<u>L47</u>	7001890.pn. cpg	0	<u>L47</u>	<u>L47</u>
<u>L46</u>	7001890.pn.	1	<u>L46</u>	<u>L46</u>
<u>L45</u>	7001890.pn. and \$ACGTTTCGAG\$	0	<u>L45</u>	<u>L45</u>
<u>L44</u>	L43	28	<u>L44</u>	<u>L44</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>				
<u>L43</u>	\$TGACTGTGAACGTTTCGAGATGA\$	137	<u>L43</u>	<u>L43</u>
<u>L42</u>	20040265912.pn. and (peg or polyethylene\$)	1	<u>L42</u>	<u>L42</u>
<u>L41</u>	20040265912.pn. and (chemotherapeutic or calicheamycin or doxorubicin or taxol or methotrexate or gemcitabine or cytarabine or vinblastin or daunorubicin or docetaxel or irinotecan or epothilone B or epothilone D or cisplatin or carboplatin or 5-fluoro-Uracil or 5fu or 5 fu)	0	<u>L41</u>	<u>L41</u>
<u>L40</u>	20040265912.pn. and (cpg or immunostim\$ or cytotox\$ or tosin)	1	<u>L40</u>	<u>L40</u>
<u>L39</u>	20040265912.pn. and (carrier or pharmaceut\$)	1	<u>L39</u>	<u>L39</u>
<u>L38</u>	20040265912.pn. and (cpg or immunostim\$) and (platelet or pdgf)	1	<u>L38</u>	<u>L38</u>
<u>L37</u>	20040265912.pn. and (cpg or immunostim\$)	1	<u>L37</u>	<u>L37</u>
<u>L36</u>	Janjic.in. and \$CACAGGCTACGGCACGCTAGAGCATCACCATGATCCTGTG\$ and (chemotherapeutic or calicheamycin or doxorubicin or taxol or methotrexate or gemcitabine or cytarabine or vinblastin or daunorubicin or docetaxel or irinotecan or epothilone B or epothilone D or cisplatin or carboplatin or 5-fluoro-Uracil or 5fu or 5 fu)	5	<u>L36</u>	<u>L36</u>
<u>L35</u>	Janjic.in. and \$CACAGGCTACGGCACGCTAGAGCATCACCATGATCCTGTG\$ (platelet derived growth factor or pdgf)same (nucleic acid ligand or aptamer)	11	<u>L35</u>	<u>L35</u>
<u>L34</u>	same (chemotherapeutic or calicheamycin or doxorubicin or taxol or methotrexate or gemcitabine or cytarabine or vinblastin or daunorubicin or docetaxel or irinotecan or epothilone B or epothilone D or cisplatin or carboplatin or 5-fluoro-Uracil or 5fu or 5 fu) and \$AACGTTTCGAG\$ (platelet derived growth factor or pdgf)same (nucleic acid ligand or aptamer)	4	<u>L34</u>	<u>L34</u>
<u>L33</u>	same (chemotherapeutic or calicheamycin or doxorubicin or taxol or methotrexate or gemcitabine or cytarabine or vinblastin or daunorubicin or docetaxel or irinotecan or epothilone B or epothilone D or cisplatin or carboplatin or 5-fluoro-Uracil or 5fu or 5 fu) and \$tgactgtgaacgttcgagatga\$ (platelet derived growth factor or pdgf)same (nucleic acid ligand or aptamer)	0	<u>L33</u>	<u>L33</u>
<u>L32</u>	same (chemotherapeutic or calicheamycin or doxorubicin or taxol or methotrexate or gemcitabine or cytarabine or vinblastin or daunorubicin or docetaxel or irinotecan or epothilone B or epothilone D or cisplatin or carboplatin or 5-fluoro-Uracil or 5fu or 5 fu)	76	<u>L32</u>	<u>L32</u>
	(platelet derived growth factor or pdgf)same (nucleic acid ligand or inhibitor or			

<u>L31</u>	aptamer) same (chemotherapeutic or calicheamycin or doxorubicin or taxol or methotrexate or gemcitabine or cytarabine or vinblastin or daunorubicin or docetaxel or irinotecan or epothilone B or epothilone D or cisplatin or carboplatin or 5-fluoro-Uracil or 5fu or 5 fu)	3515	<u>L31</u>	<u>L31</u>
<u>L30</u>	(platelet derived growth factor or pdgf) same (chemotherapeutic or calicheamycin or doxorubicin or taxol or methotrexate or gemcitabine or cytarabine or vinblastin or daunorubicin or docetaxel or irinotecan or epothilone B or epothilone D or cisplatin or carboplatin or 5-fluoro-Uracil or 5fu or 5 fu)	4419	<u>L30</u>	<u>L30</u>
<u>L29</u>	(nucleic acid ligand or aptamer) same (bivalen\$ or cpg or immunostimu\$) not (bivalen\$ near2 cation)	269	<u>L29</u>	<u>L29</u>
<u>L28</u>	20040180360.pn. and (cpg or immunostim\$)	2	<u>L28</u>	<u>L28</u>
<u>L27</u>	(nucleic acid ligand or aptamer) same (bivalen\$ or cpg or immunostimu\$)	280	<u>L27</u>	<u>L27</u>
<u>L26</u>	aptamer same (bivalen\$ or cpg or immunostimu\$)	259	<u>L26</u>	<u>L26</u>
<u>L25</u>	(gold larry or janjic).in. and (bivalen\$ or cpg or immunostimu\$) and pdgf	13	<u>L25</u>	<u>L25</u>
<u>L24</u>	(gold or janjic).in. and (bivalen\$ or cpg or immunostimu\$)	87	<u>L24</u>	<u>L24</u>
<u>L23</u>	(gold or janjic).in. and (compound or bivalent or cpg or immunostimu\$)	1056	<u>L23</u>	<u>L23</u>
<u>L22</u>	((aptamer same cpg) and (toll or tlr3 or tlr9 or tlr-3 or tlr-9))	47	<u>L22</u>	<u>L22</u>
<u>L21</u>	20040265912.pn. and toll and tlr\$ and cpg and xby and b92	1	<u>L21</u>	<u>L21</u>
<u>L20</u>	20040265912.pn. and toll and tlr\$ and cpg	1	<u>L20</u>	<u>L20</u>
<u>L19</u>	20040265912.pn. and toll and tlr\$ and aptamer and cpg	1	<u>L19</u>	<u>L19</u>
<u>L18</u>	20040265912.pn. and toll and tlr\$ and aptamer and cpg and immun\$10	1	<u>L18</u>	<u>L18</u>

*DB=PGPB; PLUR=YES; OP=ADJ*

<u>L17</u>	L8 and cpg and receptor	1	<u>L17</u>	<u>L17</u>
<u>L16</u>	L8 and cpg	1	<u>L16</u>	<u>L16</u>
<u>L15</u>	20050143332.pn. and piperazine	1	<u>L15</u>	<u>L15</u>
<u>L14</u>	(antibody or immunoglobulin or ig) same (cpg or immunostimulatory sequence) same (conjugat\$3 or link\$2 or bind or bound or complex\$2 or bonded) and (cpg same immunostimulatory)	332	<u>L14</u>	<u>L14</u>
<u>L13</u>	L9 and (cpg same immunostimulatory)	420	<u>L13</u>	<u>L13</u>

*DB=USPT; PLUR=YES; OP=ADJ*

<u>L12</u>	L9 and (cpg same immunostimulatory)	112	<u>L12</u>	<u>L12</u>
<u>L11</u>	L10	271	<u>L11</u>	<u>L11</u>

*DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ*

<u>L10</u>	(antibody or immunoglobulin or ig) same (cpg or immunostimulatory sequence) same (conjugat\$3 or link\$2 or complex\$2 or associat\$3)	1343	<u>L10</u>	<u>L10</u>
<u>L9</u>	(antibody or immunoglobulin or ig) same (cpg or immunostimulatory sequence) same (conjugat\$3 or link\$2 or bind or bound or complex\$2 or associat\$3 or bonded)	1516	<u>L9</u>	<u>L9</u>
<u>L8</u>	20040253679.pn. and toll and motif	2	<u>L8</u>	<u>L8</u>
<u>L7</u>	20040253679.pn. and toll	2	<u>L7</u>	<u>L7</u>
<u>L6</u>	L5 and (drug or bioactive or chemotherap\$) and (tubulin or nucleotide analog\$3 or nucleoside analog\$3 or alkylating agent or doxorubicin or taxol or methotrexate or gemcitabine or cytarabin or ara c or vinblatin\$1 or daunorubicin or docetaxel or irinotecan or epothilone or cisplatin or carboplatin or 5fu or fluoro uracil)	51	<u>L6</u>	<u>L6</u>

<u>L5</u>	L4 and (conjugat\$3 same (aptamer or antibody or immunoglobulin))	67	<u>L5</u>	<u>L5</u>
<u>L4</u>	(prostate specific membrane antigen or psma) same aptamer	103	<u>L4</u>	<u>L4</u>
<u>L3</u>	(prostate specific membrane antigen or psma) same (imunoglobulin or antibody) same target\$ same (drug or bioactive or chemotherap\$) and (tubulin or nucleotide analog\$3 or nucleoside analog\$3 or alkylating agent or doxorubicin or taxol or methotrexate or gemcitabine or cytarabin or ara c or vinblatin\$1 or daunorubicin or docetaxel or irinotecan or epothilone or cisplatin or carboplatin or 5fu or fluoro uracil) an aptamer	0	<u>L3</u>	<u>L3</u>
<u>L2</u>	(prostate specific membrane antigen or psma) same (imunoglobulin or antibody) same target\$ same (drug or bioactive or chemotherap\$) and (tubulin or nucleotide analog\$3 or nucleoside analog\$3 or alkylating agent or doxorubicin or taxol or methotrexate or gemcitabine or cytarabin or ara c or vinblatin\$1 or daunorubicin or docetaxel or irinotecan or epothilone or cisplatin or carboplatin or 5fu or fluoro uracil)	152	<u>L2</u>	<u>L2</u>
<u>L1</u>	(prostate specific membrane antigen or psma) same (imunoglobulin or antibody) same target\$ same (drug or bioactive or chemotherap\$)	184	<u>L1</u>	<u>L1</u>

END OF SEARCH HISTORY